Compare Quest Diagnostics Inc (DGX) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs KB Financial Group, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while KB Financial Group, Inc. trades at $122.87 (market cap $41.53B). The key difference: KB Financial Group, Inc. is the larger of the two by market cap, and KB Financial Group, Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| DGX | KB | |
|---|---|---|
Market Cap | $22.80B | $41.53B |
Sector | Health | Financials |
52-Week High | $216.02 | $123.25 |
52-Week Low | $166.42 | $77.50 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
KB Financial Group (KB) trades at $123.25, up 0.05% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, 27.82% net income margin, and 27.47% profit margin in 2025. Recent news highlights expansion into non-banking segments and dividend potential. Revenue grew to $21.23T in 2025, with net income reaching $5.83T.
The outlook remains positive with earnings growth and diversification driving upside, though technical oscillators signal overbought conditions. Risks include volatile cash flows and competitive pressures. Analyst consensus is mixed with 33% buy ratings. The stock presents value with a P/E of 11.84 but requires monitoring of execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
